Altogen Biosystems Launches New Nanoparticle Based In Vivo Transfection Reagent

Altogen Biosystems (altogen)
announced launch of novel Nanoparticle-based transfection reagent for use
in laboratories and research facilities for animal testing. Transfection is
one of the major laboratory methods used to introduce DNA and RNA molecules
into cells and tissues. This technique makes it possible to cross the
cellular barriers and deliver a gene or a small interfering RNA (siRNA)
into the cells for research or therapeutic purposes.



The company has previously developed lipid- and polymer-based in vivo
transfection reagents (altogen/mirna.htm) used for testing
pharmaceuticals in animals. Altogen Biosystems recently developed novel
nanoparticles biotechnology that allows highly efficient delivery of
various biomolecules into animal tissues via systemic administration, as
well as intraperitoneal and direct intratumoral injections.



Altogen Biosystems is focusing on commercializing pharma- and
bio-technologies, as well as providing custom laboratory research services.
The company now offers such innovative services as generation of
stably-transformed cell lines in 28-days, as well as gene silencing and
RNAi services (altogen/support.htm).



About Altogen Biosystems



Altogen Biosystems is a life sciences company located in Las Vegas,
Nevada. The company is dedicated to the engineering, marketing and
manufacture of transfection reagents and kits for intracellular and
tissue-targeted delivery of biomolecules (altogen).



Altogen Custom Services focus on providing specialized biotechnology
and pharmaceutical services, including generation of stable cell lines,
gene silencing and RNA Interference (RNAi) services, assay development,
library screening, and transfection services (altogen/support.htm).


Altogen Biosystems

altogen